Observational study of optimization of biologic therapies in rheumatoid arthritis: A single-centre experience

Rheumatology International

Volumn 34, Issue 8, 2014, Pages 1059-1063

  Maneiro, Jose Ramon ^a   Perez Pampin, Eva ^a   Salgado, Eva ^a   Carmona, Loreto ^a,b   Gomez Reino, Juan J ^a,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Abatacept; Optimization; Rheumatoid arthritis; TNF antagonists; Tocilizumab

Indexed keywords

ABATACEPT; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; TOCILIZUMAB; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DAS28; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPAIN; TIME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BLOOD SEDIMENTATION; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904856045     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2839-4     Document Type: Article

References (18)

1. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Ostergaard M (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62(1):22-32. doi:10. 1002/art.27227
2. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70(7):1216-1222. doi:10.1136/ard.2010.140129
3. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewe R, Smolen JS, Emery P, Buch MH (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976-986. doi:10.1136/ard.2009.126573
4. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, Euller-Ziegler L (2009) Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 76(4):350-355. doi:10.1016/j.jbspin.2008.11.009
5. van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF (2011) Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the Best study. Ann Rheum Dis 70(8):1389-1394. doi:10.1136/ard.2010.147751
6. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69(7):1286-1291. doi:10.1136/ard.2009. 121491
7. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ, van der Lubbe PA, de Beus WM, Grillet BA, Ronday HK, Huizinga TW, Breedveld FC, Dijkmans BA, Allaart CF (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68(6):914-921. doi:10.1136/ard.2008.092254
8. Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, Churchman SM, Quinn M, Wakefield R, Conaghan PG, Ponchel F, Emery P (2010) Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69(9):1636-1642. doi:10.1136/ard.2009.117341
9. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22):1586-1593. doi:10.1056/nejm200011303432201 (Pubitemid 32162981)
10. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35-45. doi:10.1002/art.10697 (Pubitemid 36091645)
11. Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M (1999) Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol 26(2):484-489 (Pubitemid 29066762)
12. van Vollenhoven RF, Brannemark S, Klareskog L (2004) Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 63(4):426-430
13. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM (2004) The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 50(7):2082-2093. doi:10.1002/art.20350 (Pubitemid 38924385)
14. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594-1602. doi:10.1056/nejm200011303432202
15. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1):27-35. doi:10.1002/art.20712 (Pubitemid 40129229)
16. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617):987-997. doi:10.1016/s0140-6736(08)60453-5 (Pubitemid 351392039)
17. Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC (2008) The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 67(9):1229-1234. doi:10.1136/ard.2007.083675
18. van Vollenhoven RF (2009) How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis 68(8):1237-1239. doi:10.1136/ard.2009.111682